etherna's intratumoral mRNA/LNP platform advances to clinical testing in nonmelanoma skin cancer led by Almirall
PR Newswire —
NIEL, Belgium, Feb. 24, 2026 /PRNewswire/ -- etherna, a leading provider of cutting-edge mRNA and lipid nanoparticle (LNP) technology across the biotech and pharma industry, announces that one of its key collaborators, Almirall (www.almirall.com), a leading medical dermatology company,...